Waystar Considers Potential Sale Amid Falling Market Valuation

Waystar, a prominent player in the healthcare software industry, is exploring strategic options including a potential sale, according to sources familiar with the matter. The company, which provides software solutions to streamline administrative tasks for hospitals and medical practitioners, is reportedly in the early stages of this process and has engaged investment bank Evercore for advisory services.

Based in Lehi, Utah, and Louisville, Kentucky, Waystar's market valuation has seen a significant decline, currently standing at approximately $4.8 billion following a 24% drop in its share price this year. This decline is part of a broader selloff affecting the software sector, prompting the company to consider whether investor interest in software businesses is on the rebound.

Market Challenges and Strategic Positioning

Waystar was formed through the 2017 merger of Zirmed and Navicure, both revenue management firms specializing in healthcare. The company positioned itself not as a traditional healthcare service provider but as a technology firm, aiming to capitalize on the higher valuations generally associated with tech companies. Initially, this strategy paid off, with shares climbing from $20 to a peak of $45 in 2025. However, concerns about advancements in artificial intelligence disrupting the software landscape have put pressure on the stock, as outlined in a Morgan Stanley report from July.

Waystar's major stakeholders include EQT, the Canada Pension Plan Investment Board (CPPIB), and Bain Capital, all of whom played a role in taking the company public in 2024. EQT holds the largest share at 13%, followed by CPPIB with 10%, and BlackRock Institutional Trust Company with 8%, according to LSEG data.

Potential Outcomes and Investor Sentiment

The exploration of a sale by Waystar could potentially return the company to private ownership just two years after its initial public offering. The outcome of this strategic review is uncertain, with the possibility that a sale might not materialize. The process is expected to test current investor appetite for software companies, particularly in the healthcare sector.

Neither Waystar nor Evercore has provided official comments on the matter. Similarly, EQT, CPPIB, and BlackRock have not issued statements regarding the potential sale. As the situation unfolds, industry observers will be watching closely to see how Waystar navigates these challenges and whether a sale could offer a viable path forward.